Replimune Group (REPL) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Replimune Group (NASDAQ: REPL):

• 8/7/2026 – Replimune Group was upgraded by Wedbush from “neutral” to “outperform”. They now have a $12.00 price target on the stock.
• 8/7/2026 – Replimune Group had its price target raised by JPMorgan Chase & Co. from $17.00 to $20.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Replimune Group was upgraded by Wolfe Research to “outperform”.
• 8/4/2026 – Replimune Group was upgraded by Leerink Partners from “market perform” to “outperform”. They now have a $17.00 price target on the stock, up from $11.00.
• 7/31/2026 – Replimune Group was upgraded by Wedbush from “neutral” to “outperform”. They now have a $12.00 price target on the stock, up from $9.00.
• 7/31/2026 – Replimune Group was upgraded by Piper Sandler from “hold” to “strong-buy”.
• 7/20/2026 – Replimune Group was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/2/2026 – Replimune Group was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/30/2026 – Replimune Group was upgraded by BMO Capital Markets from “underperform” to “outperform”. They now have a $16.00 price target on the stock.
• 6/30/2026 – Replimune Group had its price target raised by Wedbush from $6.00 to $9.00. They now have a “neutral” rating on the stock.
• 6/26/2026 – Replimune Group was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $17.00 price target on the stock.
• 6/18/2026 – Replimune Group was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Activity

In related news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company’s stock.

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.